Literature DB >> 12924743

Intervening effectively with drug abusers infected with HIV: taking into account the potential for cognitive impairment.

Michael Copenhaver1, S Kelly Avants, Lara A Warburton, Arthur Margolin.   

Abstract

HIV-positive drug users play a significant role in the transmission of HIV infection. Substance abuse treatment programs can potentially reduce transmission by providing HIV preventive interventions to these individuals. However, there is growing evidence suggesting that, due to a variety of factors, a substantial proportion of HIV-positive drug users may enter addiction treatment with some degree of cognitive impairment in domains that could impede their ability to learn, retain, and execute HIV preventive behaviors. Hence, in order to optimize the effectiveness of these interventions, the client's level of cognitive functioning may need to be considered. In this article an Information-Motivation-Behavioral Skills model of HIV preventive behavior is used to illustrate ways in which impairment in cognitive functioning could impede HIV preventive efforts, and present several practical strategies that front-line substance abuse counseling staff and other treatment providers can incorporate into interventions delivered to HIV-positive clients.

Entities:  

Mesh:

Year:  2003        PMID: 12924743     DOI: 10.1080/02791072.2003.10400002

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  15 in total

Review 1.  Neurocognitive impairment and HIV risk factors: a reciprocal relationship.

Authors:  Pria Anand; Sandra A Springer; Michael M Copenhaver; Frederick L Altice
Journal:  AIDS Behav       Date:  2010-12

Review 2.  Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research.

Authors:  Lisa R Norman; Michael Basso; Anil Kumar; Robert Malow
Journal:  Curr Drug Abuse Rev       Date:  2009-05

3.  A randomized controlled trial of the community-friendly health recovery program (CHRP) among high-risk drug users in treatment.

Authors:  Michael M Copenhaver; I-Ching Lee; Patrick Baldwin
Journal:  AIDS Behav       Date:  2013-11

4.  An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy.

Authors:  Michael Copenhaver; Roman Shrestha; Jeffrey A Wickersham; Damian Weikum; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2016-01-13

5.  Testing an optimized community-based human immunodeficiency virus (HIV) risk reduction and antiretroviral adherence intervention for HIV-infected injection drug users.

Authors:  Michael M Copenhaver; I-Ching Lee; Arthur Margolin; Robert D Bruce; Frederick L Altice
Journal:  Subst Abus       Date:  2011-01       Impact factor: 3.716

6.  A non-inferiority trial of an evidence-based secondary HIV prevention behavioral intervention compared to an adapted, abbreviated version: Rationale and intervention description.

Authors:  Roman Shrestha; Archana Krishnan; Frederick L Altice; Michael Copenhaver
Journal:  Contemp Clin Trials       Date:  2015-08-05       Impact factor: 2.226

Review 7.  An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research.

Authors:  Lisa R Norman; Michael Basso
Journal:  Curr Drug Abuse Rev       Date:  2015

8.  Adaptation of an evidence-based intervention targeting HIV-infected prisoners transitioning to the community: the process and outcome of formative research for the Positive Living Using Safety (PLUS) intervention.

Authors:  Michael Copenhaver; Sutopa Chowdhury; Frederick L Altice
Journal:  AIDS Patient Care STDS       Date:  2009-04       Impact factor: 5.078

9.  Dual process interaction model of HIV-risk behaviors among drug offenders.

Authors:  Susan L Ames; Jerry L Grenard; Alan W Stacy
Journal:  AIDS Behav       Date:  2013-03

10.  Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.

Authors:  Angela Di Paola; Thomas Lincoln; Daniel J Skiest; Maureen Desabrais; Frederick L Altice; Sandra A Springer
Journal:  Contemp Clin Trials       Date:  2014-09-18       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.